ACTH release in response to metyrapone in diabetes insipidus patients.
D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000328:Adult; D006259:Craniocerebral Trauma / Q000150:complications; D003919:Diabetes Insipidus / Q000503:physiopathology*; D005260:Female; D005910:Glioma / Q000150:complications; D006689:Hodgkin Disease / Q000150:complications; D006801:Humans; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008797:Metyrapone / Q000494:pharmacology*; D008875:Middle Aged; D018377:Neurotransmitter Agents / Q000502:physiology; D010871:Pinealoma / Q000150:complications; D010902:Pituitary Gland / Q000503:physiopathology*; D010912:Pituitary-Adrenal Function Tests; D012888:Skull Neoplasms / Q000150:complications; D014667:Vasopressins / Q000502:physiology*; D014882:Water-Electrolyte Balance
D018377:Neurotransmitter Agents; D014667:Vasopressins; D000324:Adrenocorticotropic Hormone; D008797:Metyrapone